Opinion|Videos|January 5, 2026
Therapeutic Potential of TYK2 Inhibition in Psoriatic Arthritis
Panelists discuss the questions below in this video. What do we know about the therapeutic potential of TYK2 inhibition in psoriatic arthritis?
Advertisement
Episodes in this series
Panelists discuss the questions below in this video.
What do we know about the therapeutic potential of TYK2 inhibition in psoriatic arthritis?
Advertisement
Related to this article
Andrea Murina, MD, weighs whether she would recommend medicine to her own children amid AI, physician burnout, and evolving residency training standards.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.
The FDA approved once-daily oral zilurgisertib for FOP in patients aged 12 years and older after the phase 2 PROGRESS trial showed reduced new heterotopic ossification vs placebo.
Approval covers patients aged ≥2 years with frequently relapsing or steroid dependent disease in complete remission.
As the FDA weighs its first psychedelic approval, Sarah Norman, MPP, says training, credentialing, and reimbursement are lagging while patients are already asking.
Pranav Garimella discusses what a potential USPSTF kidney screening recommendation could mean for high-risk adults and primary care.
Two monoclonal antibodies isolated from malaria-exposed donors blocked patient IgE from binding key alpha-gal allergens and suppressed basophil activation.
Advertisement
Advertisement
Trending on HCPLive
1
The Case for Routine Kidney Screening, With Pranav Garimella, MBBS, MPH
2
FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome
3
Zilurgisertib Receives FDA Approval for FOP in Patients 12 and Older
4
Anti-Alpha-Gal Antibodies Block IgE Binding in Alpha-Gal Syndrome
5